KR940021060A - 피부 장애 치료용 약제 - Google Patents

피부 장애 치료용 약제 Download PDF

Info

Publication number
KR940021060A
KR940021060A KR1019940006325A KR19940006325A KR940021060A KR 940021060 A KR940021060 A KR 940021060A KR 1019940006325 A KR1019940006325 A KR 1019940006325A KR 19940006325 A KR19940006325 A KR 19940006325A KR 940021060 A KR940021060 A KR 940021060A
Authority
KR
South Korea
Prior art keywords
psoriasis
dermatitis
compound
formula
skin disorder
Prior art date
Application number
KR1019940006325A
Other languages
English (en)
Other versions
KR100310665B1 (ko
Inventor
라이더 바틀렛 로버트
율리흐 바이트만 클라우스
스미쓰 쿠르츠 엘렌
Original Assignee
챠우너,브룬딘
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21915403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940021060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 챠우너,브룬딘, 훽스트 아크티엔게젤샤프트 filed Critical 챠우너,브룬딘
Publication of KR940021060A publication Critical patent/KR940021060A/ko
Application granted granted Critical
Publication of KR100310665B1 publication Critical patent/KR100310665B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

일반식(I) 또는 (Ⅱ)의 화합물 및 일반식(Ⅱ)의 화합물의 생리학적으로 허용되는 염은 건선 치료에 적합하다.
상기식에서 R1, 및 R2, R3및 X는 명세서에서 정의한 바와 같다.

Description

피부 장애 치료용 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 활성 성분으로서 일반식(I) 또는 (Ⅱ)의 화합물[여기서, 일반식(Ⅱ)의 화합물은 그대로 또는 생리학적으로 허용되는 염의 형태로 존재한다]을 함유하는 약제학적 조성물 유효량을 수용체에서 투여함을 특징으로 하여, 피부 장애를 예방하거나 치료하는 방법.
    상기식에서 R1a) 메틸, b) (C3-C6)-사이클로알킬, 또는 c) 탄소원자 사이에 하나 이상의 이중결합 또는 삼중결합을 갖는 (C2-C6)-알킬을 나타내고, R2a) -CF3또는 b) -CN을 나타내며, R3a) (C1-C4)-알킬 또는 b) 수소원자를 나타내고, X는 a) -CH- 그룹 또는 b) 질소원자를 나타낸다.
  2. 제1항에 있어서, 일반식(I) 또는 (Ⅱ)의 화합물이, R1a) 메틸, b) 사이클프로필 또는 c) -CH2-CH2-C≡CH이고, R2가 -CH3이며, R3이 메틸 수소원자이고, X가 -CH- 그룹인 화합물로 이루어진 그룹중에서 선택되는 방법.
  3. 제1항에 있어서, 화합물이 N-(4-트리플루오로메틸페닐)-2-시아노-3-하이드록시크로톤아미드 및 N-(4-트리플루오로메틸페닐)-5-메틸이속사졸-4-카복스아미드로 이루어진 그룹중에서 선택되는 방법.
  4. 제1항에 있어서, 피부장애가 건선, 심상성 건선, 발진성 건선, 홍반성 건선, 농포성 건선, 피부염, 아토피성 피부염, 알레르기성 피부염, 광알레르기성 피부염, 약물성 피부염 및 습진으로 이루어진 그룹중에서 선택되는 방법.
  5. 제4항에 있어서, 피부장애가 건선인 방법.
  6. 제1항에 있어서, 조성물을 정맥내, 경구, 국소 또는 비경구 투여하는 방법.
  7. 제1항에 있어서, 조성물을 약 500mg 이하의 고체 투여형 단위로 투여하는 방법.
  8. 각질세포 증식으로 인한 피부장애 치료를 필요로 하는 환자에게 활성 성분으로서 제1항에서 정의한 일반식(I) 또는 (II)의 화합물을 함유하는 약제학적 조성물 유효량을 투여함으로써 각질세포 증식을 억제함을 특징으로 하여, 각질 세포 증식으로부터 야기되는 피부장애를 치료하는 방법.
  9. 제8항에 있어서, 피부장애가 건선, 심상성 건선, 발진성 건선, 홍반성 건선, 농포성 건선, 피부염, 아토피성 피부염, 알레르기성 피부염, 광알레르기성 피부염, 약물성 피부염 및 습진으로 이루어진 그룹중에서 선택되는 방법.
  10. 제 8항에 있어서, 조성물을 정맥내, 경구, 국소 또는 비경구 투여하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940006325A 1993-03-31 1994-03-29 피부질환치료용약제학적조성물 KR100310665B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4122393A 1993-03-31 1993-03-31
US08/041,223 1993-03-31

Publications (2)

Publication Number Publication Date
KR940021060A true KR940021060A (ko) 1994-10-17
KR100310665B1 KR100310665B1 (ko) 2001-12-28

Family

ID=21915403

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940006325A KR100310665B1 (ko) 1993-03-31 1994-03-29 피부질환치료용약제학적조성물

Country Status (17)

Country Link
US (1) US5504084A (ko)
EP (1) EP0617959B1 (ko)
JP (1) JP2930281B2 (ko)
KR (1) KR100310665B1 (ko)
AT (1) ATE183088T1 (ko)
AU (1) AU670491B2 (ko)
CA (1) CA2120319C (ko)
CY (1) CY2207B1 (ko)
DE (1) DE69419954T2 (ko)
DK (1) DK0617959T3 (ko)
ES (1) ES2135500T3 (ko)
GR (1) GR3031264T3 (ko)
HU (1) HU216194B (ko)
IL (1) IL109151A (ko)
RU (1) RU2151597C1 (ko)
TW (1) TW314467B (ko)
ZA (1) ZA942257B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695907B2 (en) * 1994-10-17 1998-08-27 Hoechst Pharmaceuticals & Chemicals K.K. Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
CA2443285C (en) 2001-04-05 2007-08-21 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JPWO2005011669A1 (ja) * 2003-08-05 2006-09-14 大日本住友製薬株式会社 経皮投与用医薬組成物
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20090042901A1 (en) * 2005-02-02 2009-02-12 Kowa Co., Ltd. Agent for prevention/therapy of disease caused by keratinocyte growth

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3035670A1 (de) * 1980-09-22 1982-04-29 Siemens AG, 1000 Berlin und 8000 München Vorrichtung zur infusion von fluessigkeiten in den menschlichen oder tierischen koerper
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DE3927257A1 (de) * 1989-08-18 1991-02-21 Hoechst Ag Verfahren zur herstellung eines polyolefins
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
HU222234B1 (hu) * 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-Cycloalkyl-propanamides, tautomeric forms of these, their salts, method of preparation, use as drugs and preparations containing them
DE4227594A1 (de) * 1992-08-20 1994-02-24 Wacker Chemie Gmbh Synthetische Alumosilikate und ihre Verwendung als heterogene Äquilibrierungskatalysatoren

Also Published As

Publication number Publication date
US5504084A (en) 1996-04-02
JP2930281B2 (ja) 1999-08-03
AU5915794A (en) 1994-10-06
HU216194B (hu) 1999-05-28
ATE183088T1 (de) 1999-08-15
HU9400908D0 (en) 1994-06-28
TW314467B (ko) 1997-09-01
CA2120319C (en) 2009-01-06
CA2120319A1 (en) 1994-10-01
ZA942257B (en) 1994-11-16
EP0617959A1 (en) 1994-10-05
JPH06329538A (ja) 1994-11-29
IL109151A (en) 1998-12-27
KR100310665B1 (ko) 2001-12-28
DK0617959T3 (da) 2000-01-24
HUT70757A (en) 1995-10-30
EP0617959B1 (en) 1999-08-11
DE69419954D1 (de) 1999-09-16
RU2151597C1 (ru) 2000-06-27
IL109151A0 (en) 1994-06-24
DE69419954T2 (de) 2000-04-13
GR3031264T3 (en) 1999-12-31
AU670491B2 (en) 1996-07-18
ES2135500T3 (es) 1999-11-01
CY2207B1 (en) 2002-11-08
AU670491C (en) 1994-10-06

Similar Documents

Publication Publication Date Title
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
KR940014328A (ko) 인돌린 화합물
HU9303051D0 (en) Substituted quinuclidine derivatives
KR960705573A (ko) 에스트로겐 조성물 및 신경 보호 방법(Estrogen Compositions and Method for Neuroprotection)
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
BR9608435A (pt) Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas.
KR940021060A (ko) 피부 장애 치료용 약제
MX9205466A (es) Procedimiento para la preparacion de un medicamento para la administracion oral o topica en el tratamiento de leishmaniasis
HUP9802087A2 (hu) Eljárás mánia és bipoláris rendellenesség kezelésére alkalmas gyógyászati készítmények előállítására
KR970025615A (ko) 암 전이 억제제
HUP0300585A2 (hu) Eljárás azalidet tartalmazó antibiotikum-készítmények alkalmazására emlősök bakteriális és protozoa fertőzésének kezelésére vagy megelőzésére
CA2127542A1 (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
AU3623299A (en) Benzofuroxan derivatives and their use in treating angina pectoris
US4806530A (en) Pharmaceutical compositions based on diltiazem and lysine acetylsalicylate
US5905069A (en) Methods of decreasing or preventing pain using spicamycin or derivatives thereof
FI104071B1 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi
KR950701929A (ko) 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 황-함유 포스포네이트 화합물(sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism)
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
KR927002224A (ko) 항종양효과증강제 및 항종양제
KR880013562A (ko) 7-티아프로스타글란딘e₁ 또는 그의 유도체를 함유하는 당뇨병치료 조성물
KR910015301A (ko) 수면 무호흡증의 치료방법
KR910011820A (ko) Ltb4 합성 저해제
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
KR930004307A (ko) 축합된 피리미딘 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120907

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20130906

Year of fee payment: 13

EXPY Expiration of term